GlassScriptPhysician profile
Kathy You
NPI 1861924169
$5,992.73
in general payments reported to CMS, 2019-2025
50 companies · $2,251 in 2025
The $2,251 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $54.20 · 2022: $585 · 2023: $893 · 2024: $2,210 · 2025: $2,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,165 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,164.68 |
| Education | $188.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $514.66 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $442.56 | 2022-2025 | Calquence, Tagrisso, Lynparza |
| Incyte Corporation | $435.89 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Merck Sharp & Dohme LLC | $296.82 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $255.16 | 2022-2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $245.31 | 2023-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Pharmaessentia USA Corporation | $240.59 | 2024-2025 | Besremi |
| Beigene USA, INC. | $233.95 | 2023-2025 | Brukinsa, Tevimbra |
| Daiichi Sankyo INC. | $208.40 | 2023-2025 | Enhertu, Vanflyta |
| Ipsen Biopharmaceuticals, INC | $201.32 | 2023-2025 | Onivyde, Somatuline Depot |
| Astellas Pharma US INC | $192.58 | 2023-2025 | Padcev, Xtandi, Xospata |
| Pfizer INC. | $186.51 | 2024-2025 | |
| Amgen INC. | $168.28 | 2021-2022 | |
| Beone Medicines USA, INC. | $165.71 | 2025 | Brukinsa |
| Emd Serono, INC. | $160.36 | 2023-2025 | Bavencio |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $154.74 | 2021-2025 | Tecentriq, Polivy |
| Lilly USA, LLC | $152.32 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $145.75 | 2024-2025 | |
| Exelixis INC. | $125.93 | 2024-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $124.62 | 2022-2025 | Opdivo |
| Aveo Pharmaceuticals, INC. | $103.19 | 2023-2025 | Fotivda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.65 | 2023-2025 | Gilotrif |
| Janssen Biotech, INC. | $93.97 | 2022-2024 | Carvykti |
| Bayer Healthcare Pharmaceuticals INC. | $85.43 | 2023-2025 | |
| Glaxosmithkline, LLC. | $83.72 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Jazz Pharmaceuticals INC. | $76.79 | 2024-2025 | |
| Genmab U.S., INC. | $75.39 | 2023-2024 | Epkinly |
| Adc Therapeutics America, INC. | $54.27 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $53.70 | 2024-2025 | Monoferric |
| Agios Pharmaceuticals, INC. | $53.30 | 2024-2025 | Pyrukynd |
| Karyopharm Therapeutics INC. | $47.79 | 2023-2024 | Xpovio |
| Adaptive Biotechnologies Corporation | $43.94 | 2022-2024 | Clonoseq |
| Mirati Therapeutics, INC. | $41.61 | 2023-2024 | Krazati |
| Gilead Sciences, INC. | $40.07 | 2024 | |
| Eisai INC. | $38.86 | 2025 | |
| Syndax Pharmaceuticals, INC. | $33.20 | 2025 | |
| Alexion Pharmaceuticals, INC. | $31.58 | 2025 | Ultomiris |
| Blueprint Medicines Corporation | $30.21 | 2024 | Ayvakit |
| Immunocore Limited | $27.75 | 2024 | Kimmtrak |
| Array Biopharma INC | $27.70 | 2025 | Braftovi, Lorbrena, Mektovi |
| Shield Therapeutics INC | $25.03 | 2024 | |
| Caris Mpi, INC. | $24.61 | 2025 | Mi Cancer Seek |
| Servier Pharmaceuticals LLC | $22.27 | 2025 | |
| Immunogen, INC. | $21.30 | 2023 | Elahere |
| Foundation Medicine, INC. | $20.59 | 2023 | Foundationone Liquid Cdx |
| Coherus Oncology, INC. | $20.36 | 2022 | |
| Puma Biotechnology, INC. | $19.08 | 2024 | |
| Dendreon Pharmaceuticals LLC | $17.22 | 2025 | Provenge |
| Mckesson Medical-Surgical, INC. | $15.00 | 2021 | |
| Progenics Pharmaceuticals, INC. | $13.69 | 2023 | Pylarify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy You listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.